Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Kilbourn

P3.09-18 Identification of MET Exon 14 Skipping Mutations by FusionPlexTM Solid Tumor Panel

Journal of Thoracic Oncology

English

Related publications

OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations

Journal of Thoracic Oncology

English

P1.13-41 in Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers With MET Mutations Including Exon 14 Skipping

Journal of Thoracic Oncology

English

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

Journal of Thoracic Oncology

English

OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress

Journal of Thoracic Oncology

English

Brief Report: DNA-based Versus RNA-based Detection of MET Exon 14 Skipping Events in Lung Cancer

Journal of Thoracic Oncology

English

P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers

Journal of Thoracic Oncology

English

Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib

Journal of Thoracic Oncology

English

Personalized Exon Skipping Strategies to Address Clustered Non-Deletion Dystrophin Mutations

Neuromuscular Disorders

English

Exonic Mutations in the SLC12A3 Gene Cause Exon Skipping and Premature Termination in Gitelman Syndrome

Journal of the American Society of Nephrology : JASN

Medicine

Nephrology

2014

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Kilbourn

P3.09-18 Identification of MET Exon 14 Skipping Mutations by FusionPlexTM Solid Tumor Panel

Related publications

OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations

P1.13-41 in Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers With MET Mutations Including Exon 14 Skipping

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress

Brief Report: DNA-based Versus RNA-based Detection of MET Exon 14 Skipping Events in Lung Cancer

P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers

Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib

Personalized Exon Skipping Strategies to Address Clustered Non-Deletion Dystrophin Mutations

Exonic Mutations in the SLC12A3 Gene Cause Exon Skipping and Premature Termination in Gitelman Syndrome